Mikhail A. Gomberg

Mikhail A. Gomberg

Auto-generated profile, based on publicly available information

Mikhail A. Gomberg

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2016 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
JJJørgen Skov Jensen
Jørgen Skov Jensen
MCM. Cusini
M. Cusini
MGM. Gomberg
M. Gomberg
HMH. Moi
H. Moi

1 May 2009 in International Journal of STD & AIDS
Verified
Journal Article
Open access
PFP French
P French
MGM Gomberg
M Gomberg
MJM Janier
M Janier
BSB Schmidt
B Schmidt
PVP van Voorst Vader
P van Voorst Vader
HYH Young
H Young
The online version of this article can be found at: DOI: 10.1258/ijsa.2008.00851

20 June 2018 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
PHP. Horner
P. Horner
GDG. Donders
G. Donders
MCM. Cusini
M. Cusini
MGM. Gomberg
M. Gomberg
JJJ.S. Jensen
J.S. Jensen
MUM. Unemo
M. Unemo

24 August 2017 in International Journal of STD & AIDS
Verified
Journal Article
Open access
RPRajul Patel
Rajul Patel
OKOliver J Kennedy
Oliver J Kennedy
ECEmily Clarke
Emily Clarke
AGAnna Geretti
Anna Geretti
ANArvid Nilsen
Arvid Nilsen
EFElizabeth Foley
Elizabeth Foley
Genital herpes is one of the commonest sexually transmitted infections worldwide. Using the best available evidence, this guideline recommends strategies for diagnosis, management, and follow-up of the condition as well as for minimising transmission. Early recognition and initiation of therapy is key and may reduce the duration of illness or avoid hospitalisation with complications, including urinary retention, meningism, or severe systemic illness. The guideline covers a range of common clinical scenarios, such as recurrent genital herpes, infection during pregnancy, and co-infection with human immunodeficiency virus.

3 February 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
Alexander GuschinAlexander Guschin
Alexander Guschin
PRPavel Ryzhikh
Pavel Ryzhikh
TRTatiana Rumyantseva
Tatiana Rumyantseva
MGMikhail Gomberg
Mikhail Gomberg
MUMagnus Unemo
Magnus Unemo
Azithromycin has been widely used for Mycoplasma genitalium treatment internationally. However, the eradication efficacy has substantially declined recent decade. In Russia, josamycin (another macrolide) is the recommended first-line treatment for M. genitalium infections, however, no data regarding treatment efficacy with josamycin and resistance in M. genitalium infections have been internationally published. We examined the M. genitalium prevalence in males attending an STI clinic in Moscow, Russia from December 2006 to January 2008, investigated treatment efficacy with josamycin in male urethritis, and monitored the M. genitalium DNA eradication dynamics and selection of macrolide resistance in M. genitalium during this treatment. Microscopy and real-time PCRs were used to diagnose urethritis and non-viral STIs, respectively, in males (n = 320). M. genitalium positive patients were treated with recommended josamycin regimen and treatment efficacy was monitored using quantitative real-time PCR. Macrolide resistance mutations were identified using sequencing of the 23S rRNA gene. Forty-seven (14.7%) males were positive for M. genitalium only and most (85.1%) of these had symptoms and signs of urethritis. Forty-six (97.9%) males agreed to participate in the treatment efficacy monitoring. All the pre-treatment M. genitalium specimens had wild-type 23S rRNA. The elimination of M. genitalium DNA was substantially faster in patients with lower pre-treatment M. genitalium load, and the total eradication rate was 43/46 (93.5%). Of the six patients with high pre-treatment M. genitalium load, three (50%) remained positive post-treatment and these positive specimens contained macrolide resistance mutations in the 23S rRNA gene, i.e., A2059G (n = 2) and A2062G (n = 1). M. genitalium was a frequent cause of male urethritis in Moscow, Russia. The pre-treatment M. genitalium load might be an effective predictor of eradication efficacy with macrolides (and possibly additional antimicrobials) and selection of macrolide resistance. Additional in vivo and in vitro data are crucial to support the recommendation of using josamycin as first-line treatment for M. genitalium infections in Russia. It would be valuable to develop international M. genitalium management guidelines, and quantitative diagnostic PCRs determining also M. genitalium load and resistance mutations (for macrolides and ideally also moxifloxacin) should ideally be recommended.

1 January 2011 in International Journal of STD & AIDS
Verified
Journal Article
Open access
RPR Patel
R Patel
SAS Alderson
S Alderson
AGA Geretti
A Geretti
ANA Nilsen
A Nilsen
EFE Foley
E Foley
HMH Moi
H Moi
This is the guideline for genital herpes simplex virus (HSV) management for the IUSTI/WHO Europe, 2010. They describe the epidemiology, diagnosis, clinical features, treatment and prevention of genital HSV infection. They include details on the management of HSV in pregnancy, those who are immunocompromised and the clinical investigation and management of suspected HSV-resistant disease.